BeyondSpring, Inc. stock is up 34.07% since 30 days ago. The next earnings date is Jan 2, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 57.14% of the previous 6 February’s closed higher than January.
Plinabulin, a selective immune-modulating microtubule-binding agent, has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. BeyondSpring Inc. is a clinical stage biopharmaceutical company. Company engages in the development of three small molecule immune agents in preclinical stages; and drug development platform.
Unlock Exclusive Market Insights! Receive timely updates on market developments. Sign up & stay informed!